课题基金 / 基金详情

Metabolic regulation of human erythropoiesis

Metabolic regulation of human erythropoiesis
人类红细胞生成的代谢调节
批准号:
9755410
负责人:
NAOMI TAYLOR
金额:
$13.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

NAOMI TAYLOR的其他基金

相似基金

相关文献

中文摘要
翻译
项目3摘要 人红细胞生成的代谢调控 造血干细胞(HSCs)的自我更新能力受细胞代谢状态的控制,但 营养物质的进入和新陈代谢可能有助于HSC对 淋巴系、髓系或红系的命运直到最近才被考虑。这个项目的总体目标是 项目是发展对细胞新陈代谢在生理和心理上的作用的机械性理解。 红血球生成紊乱。我们的研究解决了营养物质的运输和利用调节 正常和病理性人类红系分化。我们之前的数据显示,葡萄糖 转运蛋白Glut1只有在人类红系分化的最后有丝分裂(Montel- Hgen等人的观点。细胞2008),而谷氨酰胺转运体ASCT2在所有的肝星状细胞上表达。我们 确定下调ASCT2或阻断谷氨酰胺代谢可消除红系 分化,并使促红细胞生成素治疗的造血干细胞走向髓系命运。相比之下,转移葡萄糖 进入磷酸戊糖途径,远离糖酵解,加速红细胞生成(Oburoglu等人。细胞 干细胞2014)。在目标1中,我们将使用我们独特的逆转录病毒包膜受体结合域集合 (RBDS),作为溶质载体(SLC)营养转运体的特定配体,以表征阶段- 转运蛋白的特定表达和功能,并决定转运蛋白调控的阵列 正常情况下的红系祖细胞以及核层改变的红系祖细胞(有 项目4),在TET2缺陷的骨髓增生异常综合征模型中,以及在RPL5和RPL11缺陷的模型中 钻石黑粉贫血模型(项目1)。在目标2中,我们将评估来自稳定的代谢通量 葡萄糖、谷氨酰胺和脂肪酸同位素示踪剂,阐明代谢网络和代谢产物 调节正常和紊乱的红细胞生成。这些研究将批判性地解决我们的假设 资源利用支配着早期和晚期的红系分化,在一个层面上,不仅仅是提供 细胞分裂所需的三磷酸腺苷、氨基酸和类脂。我们认为新陈代谢变化 有助于特定阶段的表观遗传、转录和翻译红系调节计划,这些计划 将与项目2一起进行评估。我们预计将这些数据集成到计划项目中将 确定控制特定阶段红系转变的养分通量和利用,先驱养分 在红系疾病中发现转运蛋白生物标记物,并促进营养物质的操纵 红系细胞生理和病理分化的转运蛋白和代谢网络 和生存。
英文摘要
Project 3 Abstract Metabolic regulation of human erythropoiesis The self renewal capacity of hematopoietic stem cells (HSCs) is controlled by the cells' metabolic state but the possibility that nutrient entry and metabolism contribute to the differential commitment of an HSC to a lymphoid, myeloid or erythroid lineage fate was not considered until very recently. The overall goal of this project is to develop a mechanistic understanding of the role of cell metabolism in physiological and disordered erythropoiesis. Our studies address the hypothesis that nutrient transport and utilization regulate both normal and pathological human erythroid differentiation. Our previous data show that the glucose transporter Glut1 is only upregulated during the final mitoses of human erythroid differentiation (Montel- Hagen et al. Cell 2008) whereas the glutamine transporter ASCT2 is expressed on all HSCs. We determined that down regulation of ASCT2 or blocking glutamine metabolism abrogates erythroid differentiation and skews erythropoietin-treated HSCs towards a myeloid fate. In contrast, diverting glucose into the pentose phosphate pathway, away from glycolysis, accelerates erythropoiesis (Oburoglu et al. Cell Stem Cell 2014). In Aim 1, we will use our unique collection of retroviral envelope receptor binding domains (RBDs), that function as specific ligands of solute carrier (SLC) nutrient transporters, to characterize stage- specific expression and function of transporters and determine the array of transporters regulating erythropoiesis in normal conditions as well as in erythroid progenitors with altered nuclear lamins (with Project 4), in a TET2-deficient model of myelodysplastic syndrome, and in RPL5- and RPL11-deficient models of Diamond Blackfan anemia (with Project 1). In Aim 2, we will assess metabolic fluxes from stable glucose, glutamine, and fatty acid isotope tracers, elucidating the metabolic networks and metabolites that regulate normal and perturbed erythropoiesis. These studies will critically address our hypothesis that fuel resource utilization governs early and terminal erythroid differentiation, at a level beyond simply providing the ATP, amino acids and lipids that are required for cell division. We propose that metabolic changes contribute to stage-specific epigenetic, transcriptional and translational erythroid regulatory programs which will be evaluated with Project 2. We anticipate that integration of these data within the Program Project will identify the nutrient fluxes and utilization that control stage-specific erythroid transitions, pioneer nutrient transporter biomarker discovery in erythroid disorders, and promote the manipulation of nutrient transporters and metabolic networks that orient physiological and pathological erythroid cell differentiation and survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ZAP-70 Deficiency: A model for gene therapy studies
ZAP-70 Deficiency: A model for gene therapy studies
ZAP-70 Deficiency: A model for gene therapy studies
ZAP-70 Deficiency: A model for gene therapy studies
海外基金